AstraZeneca plc (ADR) (NYSE:AZN)

CAPS Rating: 4 out of 5

The Company discovers, develops, manufactures and markets prescription pharmaceuticals for important areas of healthcare: cancer, cardiovascular, gastrointestinal, infection, neuroscience, and respiratory and inflammation.

Results 1 - 20 of 114 : 1 2 3 4 5 6 Next »

Recs

0
Member Avatar pest1948 (< 20) Submitted: 12/28/2014 3:52:20 PM : Outperform Start Price: $68.74 AZN Score: -1.12

appl

Recs

0
Member Avatar Herbstmd (52.80) Submitted: 8/12/2014 12:52:54 PM : Underperform Start Price: $66.61 AZN Score: +5.54

Government over regulation

Recs

0
Member Avatar charandy (39.64) Submitted: 8/12/2014 5:43:40 AM : Outperform Start Price: $66.41 AZN Score: -5.26

Depakote

Recs

0
Member Avatar JCG (< 20) Submitted: 5/26/2014 6:14:42 PM : Outperform Start Price: $68.20 AZN Score: -9.46

Astrazeneca makes lots of money

Recs

0
Member Avatar cajun1958 (24.21) Submitted: 5/25/2014 7:17:29 PM : Underperform Start Price: $68.20 AZN Score: +9.46

Whatever value PFE's merger attempt brought to light in AZN, it appears doubtful the company will be much more than a good yield instrument with a top end in the low 70s,

Recs

0
Member Avatar afewgoodstocks11 (24.96) Submitted: 2/21/2014 1:43:37 PM : Outperform Start Price: $37.84 AZN Score: +14.84

Div. (Yield) $2.70 (3.1%)
Current Yield . . . . . . 6.855%

Recs

0
Member Avatar Teacherman333 (84.93) Submitted: 7/25/2013 11:42:21 AM : Outperform Start Price: $46.91 AZN Score: +17.60

For reference point and to allow for comments by others. As of the end of March, 2013.

ROE 25.84%
Trailing PE 10.03
PB 2.83
Div yield 7.60%

Recs

0
Member Avatar IlluminatInvest (50.48) Submitted: 3/18/2013 5:02:08 PM : Outperform Start Price: $42.19 AZN Score: +27.45

Restructuring will cut fat while they restock their drug pipeline, and should eventually allow them to continue raising their dividend.

Recs

0
Member Avatar IlanBigfoot (87.25) Submitted: 12/30/2012 10:45:05 PM : Outperform Start Price: $40.78 AZN Score: +17.88

High yield strategy: TMFHighYield says to look for "high dividend payers from the S&P 500 from diverse sectors, relatively low debt, and a history of increasing dividend payments." This is my Health Care pick.
$46.88

Recs

1
Member Avatar gsauter157 (< 20) Submitted: 8/28/2012 9:05:49 AM : Outperform Start Price: $40.91 AZN Score: +18.97

New CEO

Recs

1
Member Avatar rainmaker59 (45.15) Submitted: 7/17/2012 3:19:51 PM : Outperform Start Price: $39.68 AZN Score: +19.01

Meets my metrics of low PE, high yield, eps, beta, roe and net profit. And 10 percent below 52-week high.

Recs

1
Member Avatar ihaveabaddober (31.45) Submitted: 5/23/2012 3:48:43 PM : Outperform Start Price: $35.08 AZN Score: +36.58

DIVIDEND/ROE MONSTER

Recs

0
Member Avatar outoffocus (23.23) Submitted: 4/27/2012 2:39:36 PM : Outperform Start Price: $37.38 AZN Score: +34.13

low p/e high div yield

Recs

0
Member Avatar Buffettinvestor (50.37) Submitted: 4/3/2012 3:01:59 PM : Outperform Start Price: $38.44 AZN Score: +29.53

Very cheap stock, with under 6 p/e, but still earning incredible returns on capital. Has been hit too hard among the pharmaceutical firms. Great contrarian play, with a great dividend Yield of over 6%.

Recs

0
Member Avatar recklessfier (< 20) Submitted: 3/8/2012 2:14:42 AM : Outperform Start Price: $38.44 AZN Score: +24.70

FDL1

Recs

0
Member Avatar campwt00global (32.75) Submitted: 1/4/2012 8:41:56 AM : Outperform Start Price: $38.96 AZN Score: +10.97

http://seekingalpha.com/article/317243-the-5-yield-solution

Recs

1
Member Avatar Chemdawg (25.44) Submitted: 10/8/2011 1:57:28 PM : Outperform Start Price: $38.51 AZN Score: -0.40

buybacks...great yield.... 10% off 52 week low

Recs

0
Member Avatar jmt587 (99.85) Submitted: 9/22/2011 2:10:02 PM : Outperform Start Price: $34.89 AZN Score: +9.33

Long Term Outperform.

Recs

0
Member Avatar d0w0kelley (< 20) Submitted: 8/28/2011 12:27:40 AM : Outperform Start Price: $38.12 AZN Score: +4.24

Large Cap stock trading above their 14-day SMA

Recs

0
Member Avatar STORMSTOCKER (< 20) Submitted: 8/11/2011 4:58:55 PM : Outperform Start Price: $36.77 AZN Score: +9.17

A MAJOR DRUG COMPANY THAT HAS BEEN BEATEN DOWN.

Results 1 - 20 of 114 : 1 2 3 4 5 6 Next »

Featured Broker Partners


Advertisement